Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 7Recruiting 4Completed 4Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 29Carboplatin 15Cisplatin 13Nivolumab 12atezolizumab 10Radiotherapy 10Paclitaxel 10Ipilimumab 10venetoclax 9Pemetrexed 9Docetaxel 9durvalumab 8Gemcitabine 8fludarabine 7Specimen Handling 7Cyclophosphamide 7Bevacizumab 7tislelizumab 6fludarabine phosphate 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6enzalutamide 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Mitoxantrone × 90 days × Clear all
NCT03150004 2026-03-30

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Medical College of Wisconsin

Phase 2 Terminated
53 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡